The China market is highly diversified and extremely competitive, therefore ethics and safety to meet ... unmet medical needs is key
In Conversation
Unlike oncology, the inhalation market in China is far less crowded and developed
I did not want to work on an antibody similar to the dozens already in clinical trials, I wanted to find a differentiator!
Like many other Big Pharma companies, the global corporate organization has traditionally been more US- and Euro-centric but today, it needs to be more China-centric.
What McKinsey brings to the table is a globalized view combined with deep local expertise.
China is a market of great opportunities. Nowhere else in the world do you see healthcare needs growing at such a scale and speed. These opportunities…
Maintaining quality standards is not just about having the right regulations or knowhow, it boils down doing the right thing every time, day in, day out
In general, our management team is more familiar with the European and US markets, but we are certainly not going to neglect the China market.
Currently, I believe that we might be the only company in the world working in the area of ovine heparin
In 2007, we worked on only six innovative compounds. Since 2015, however, we have worked on over 20 innovative drug compounds every year
China is today becoming a major driver of business growth for the company globally
One of our defining principles has always been our ‘Two Countries, One System’ philosophy. We operate in the US and China under the same quality systems,…
